Kademani D. Oral cancer . Mayo Clin Proc, 2007, 82(7): 878-887. Rini B. Future approaches in immunotherapy . Semin Oncol, 2014, 41(Suppl 5): S30-40. Malek TR. The biology of interleukin-2 . Annu Rev Immunol, 2008, 26: 453-479. Boyman O, Purton JF, Surh CD, et al. Cytokines and T-cell homeostasis . Curr Opin Immunol, 2007, 19(3): 320-326. 闫轶鹏, 张青宜, 贺立山. 白血病患者化疗后应用IL-2对T淋巴细胞亚群的影响.细胞与分子免疫学杂志, 2010, 26(9): 898-899. Krieg C, Létourneau S, Pantaleo G, et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells . Proc Natl Acad Sci USA, 2010, 107(26): 11906-11911. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications . Curr Opin Oncol, 2003, l5(6): 431-439. Hu SX, Wang S, Wang JP, et al. Expression of endogenous granzyme B in a subset of human primary breast carcinomas . Br J Cancel, 2003, 89(1): 135-139. 石群立, 周晓军, 孟奎, 等. 穿孔素与颗粒酶B在鼻NK/T细胞淋巴瘤诊断中的意义 .临床与实验病理学杂志, 2004, 20(5): 580-584. Lehhman C, Zeis M, Schmitz N, et al. Impaired binding of perforin the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells . Blood, 2000, 96(2):594-600. Spitzer JH, Meadow GG. Modulation of perforin, granzyme A, and granzyme B in murine natural killer (NK), IL-2 stimulated NK, and lymphokine-activated killer cells by alcohol consumption . Cell Immunol, 1999, 194(2): 205-212. Lehmann C, Zeis M, Uharek L. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells . Br J Heamatol,2001, 114(3): 660-665. |